Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07481981 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Insmed Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT07481981 is a Phase 3 study that is actively recruiting participants, run by Insmed Incorporated. The registered enrollment target is 344 participants.
The verdict
NCT07481981, a Phase 3 study, is actively recruiting participants, sponsored by Insmed Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-06-26 |
| Est. Completion | 2029-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07481981
The ClinicalTrials.gov registry entry for NCT07481981 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07481981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07481981 about?
NCT07481981 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)". The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
What is the current status of trial NCT07481981?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2026-06-26. Estimated completion is 2029-01-28.
What interventions are being tested in trial NCT07481981?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT07481981?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.